11月18日，港股创新药ETF鹏华（159286）跌1.72%，成交额8386.77万元。当日份额增加300.00万份， 最新份额为6.73亿份，近20个交易日份额增加6300.00万份。最新资产净值计算值为6.13亿元。港股创新 药ETF鹏华（159286）业绩比较基准为国证港股通创新药指数收益率(经汇率调整后)，管理人为鹏华基 金管理有限公司，基金经理为林嵩、张羽翔，成立（2025-08-20）以来回报为-8.91%，近一个月回报 为-0.55%。风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息 （包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个 人投资建议。 来源：视频滚动新闻 ...

港股创新药ETF鹏华（159286）业绩比较基准为国证港股通创新药指数收益率(经汇率调整后)，管理人 为鹏华基金管理有限公司，基金经理为林嵩、张羽翔，成立（2025-08-20）以来回报为-5.05%，近一个 月回报为-0.05%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 来源：新浪基金∞工作室 11月13日，港股创新药ETF鹏华（159286）涨4.40%，成交额1.77亿元。当日份额减少2500.00万份，最 新份额为6.78亿份，近20个交易日份额增加8400.00万份。最新资产净值计算值为6.44亿元。 ...

Group 1 - The core viewpoint indicates that the innovative drug sector in Hong Kong is showing clear signs of bottoming out, supported by several factors [1] - BD (Business Development) transactions have started to recover since October, with historical data showing that transactions from October to January account for over 50% of the annual total, and transaction amounts can reach 60% to 70% of the yearly total [1] - Positive data from ESMO (European Society for Medical Oncology) has emerged, with several important clinical studies, such as AK112 and 3SB707, showing promising results, which is expected to catalyze further trading and stock price increases [1] - The valuation of innovative drugs has reached an absolute bottom, with some companies having little room for further decline [1] Group 2 - As of October 21, 2025, the National Securities Hong Kong Stock Connect Innovative Drug Index (987018) shows mixed performance among its constituent stocks, with notable gainers including CloudTop New Drug (01952) up 5.29% and Zai Lab (09688) up 1.80%, while major decliners include Juno Therapeutics-B (02617) down 6.82% [2] - The Hong Kong Innovative Drug ETF (159286) closely tracks the National Securities Hong Kong Stock Connect Innovative Drug Index and has seen a slight increase of 0.22%, with the latest price at 0.93 yuan [2] - As of September 30, 2025, the top ten weighted stocks in the National Securities Hong Kong Stock Connect Innovative Drug Index account for 71.83% of the index, including companies like BeiGene (06160) and Innovent Biologics (09926) [2]

风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 10月16日，港股创新药ETF鹏华（159286）涨2.37%，成交额2.17亿元。当日份额增加700.00万份，最新 份额为5.94亿份，近20个交易日份额增加9800.00万份。最新资产净值计算值为5.62亿元。 港股创新药ETF鹏华（159286）业绩比较基准为国证港股通创新药指数收益率(经汇率调整后)，管理人 为鹏华基金管理有限公司，基金经理为林嵩、张羽翔，成立（2025-08-20）以来回报为-5.38%，近一个 月回报为-7.86%。 来源：新浪基金∞工作室 ...

Core Viewpoint - The Hong Kong Innovative Drug ETF managed by Penghua experienced a decline of 2.30% on October 10, with a trading volume of 121 million yuan, indicating a challenging market environment for innovative drug investments [1] Fund Performance - The fund's latest net asset value is calculated at 538 million yuan, with a total share increase of 10 million shares on the same day, bringing the total shares to 559 million [1] - Over the past 20 trading days, the fund's shares have decreased by 41 million [1] - Since its inception on August 20, 2025, the fund has returned -3.67%, while the return over the past month is -5.25% [1] Management Information - The fund is managed by Penghua Fund Management Co., Ltd., with fund managers Lin Song and Zhang Yuxiang overseeing its operations [1]

港股创新药ETF鹏华（159286）业绩比较基准为国证港股通创新药指数收益率(经汇率调整后)，管理人 为鹏华基金管理有限公司，基金经理为林嵩、张羽翔，成立（2025-08-20）以来回报为1.77%。 9月17日，港股创新药ETF鹏华（159286）跌0.30%，成交额9891.35万元。当日份额减少1000.00万份， 最新份额为5.34亿份。最新资产净值计算值为5.43亿元。 来源：新浪基金∞工作室 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 ...